Filing Flows › Coherus Oncology (CHRS) › Q2 2026 › vs Q1 2026
Coherus Oncology (CHRS) Q2 2026 vs Q1 2026 (quarter over quarter)
Coherus Oncology's revenue rose $2.0M (+16%) from $12.3M in Q1 2026 to $14.3M in Q2 2026. The biggest changes: Toripalimab +$1.8M (+15%); Other revenue +$187K (+37%).
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Toripalimab | $13.6M | $11.8M | $1.8M | +15% |
| Other revenue | $694K | $507K | $187K | +37% |
| Revenue | $14.3M | $12.3M | $2.0M | +16% |
| Income tax benefit | $12.7M | −$1.4M | $14.1M | — |
| Net loss | $20.6M | $38.3M | −$17.7M | -46% |
| Costs & expenses | $47.7M | $50.6M | −$3.0M | -6% |
| Operating costs | $46.6M | $48.5M | −$1.8M | -4% |
| Interest & other, net | $1.0M | $784K | $232K | +30% |
| Cost of revenue | $4.2M | $3.8M | $428K | +11% |
| Research & development | $21.4M | $21.5M | −$101K | -0.5% |
| SG&A | $21.0M | $23.1M | −$2.1M | -9% |
| Operating cash sources | $65.5M | $61.2M | $4.4M | +7% |
| Depreciation & amortization | $862K | $881K | −$19K | -2% |
| Share-based compensation | $2.6M | $2.4M | $198K | +8% |
| Cash used in operations | $62.1M | $57.9M | $4.2M | +7% |
| Net loss absorbed | $20.6M | $38.3M | −$17.7M | -46% |
| Working capital & other | $44.9M | $22.8M | $22.1M | +97% |
Questions
How much did Coherus Oncology's revenue grow quarter over quarter in Q2 2026?
Coherus Oncology's revenue rose $2.0M (+16%) from $12.3M in Q1 2026 to $14.3M in Q2 2026.
What drove Coherus Oncology's revenue change in Q2 2026?
Toripalimab +$1.8M (+15%); Other revenue +$187K (+37%).